Spots Global Cancer Trial Database for resectable hepatocellular carcinoma
Every month we try and update this database with for resectable hepatocellular carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer | NCT04721132 | Resectable Hepa... Stage I Hepatoc... Stage IA Hepato... Stage IB Hepato... Stage II Hepato... | Atezolizumab Bevacizumab Therapeutic Con... | 18 Years - | M.D. Anderson Cancer Center | |
| Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer | NCT04856046 | Resectable Hepa... | Biospecimen Col... Electronic Heal... | 18 Years - | Mayo Clinic | |
| Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer | NCT04856046 | Resectable Hepa... | Biospecimen Col... Electronic Heal... | 18 Years - | Mayo Clinic | |
| Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma | NCT05519410 | Resectable Hepa... | Sintilimab and ... HAIC-FOLFOX | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma | NCT04701060 | Resectable Hepa... | Camrelizumab:20... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma | NCT04834986 | Resectable Hepa... | Tislelizumab co... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer | NCT03222076 | Hepatocellular ... Resectable Hepa... | Ipilimumab Nivolumab | 18 Years - | M.D. Anderson Cancer Center | |
| Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma | NCT04834986 | Resectable Hepa... | Tislelizumab co... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma. | NCT05807776 | Resectable Hepa... | Tislelizumab Tislelizumab, L... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING) | NCT05578430 | Resectable Hepa... | Cadonilimab TACE Surgery | 18 Years - 75 Years | Sun Yat-sen University | |
| Surgical Resection for Hepatocellular Carcinoma | NCT06013657 | Resectable Hepa... | Liver Resection | - | Dr Cipto Mangunkusumo General Hospital | |
| SIRT With Tremelimumab and Durvalumab for Resectable HCC | NCT05701488 | Resectable Hepa... Hepatocellular ... Hepatocellular ... | Durvalumab Tremelimumab SIRT | 18 Years - | Dana-Farber Cancer Institute | |
| 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant | NCT02379377 | Adult Hepatocel... Resectable Hepa... Cholangiocarcin... Benign Liver Tu... Metastases to L... | Fluorine F 18 L... Carbon C 11 Ace... Positron Emissi... Laboratory Biom... Fluorine F 18 2... | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
